U.S., June 11 -- ClinicalTrials.gov registry received information related to the study (NCT07012304) titled 'Gecacitinib for cGVHD: Safety and Efficacy in Patients After >=2 Lines of Prior Therapy' on May 09.
Brief Summary: Chronic Graft-versus-Host Disease (cGVHD) is a common late complication following allogeneic hematopoietic stem cell transplantation and a leading non-relapse cause of death. It is often treatment-refractory, significantly affecting patients' quality of life and prognosis. This study will evaluate the feasibility, safety, and tolerability of gecacitinib, a novel JAK and ACVR1 inhibitor, in 24 patients with moderate-to-severe cGVHD who have undergone two or more prior therapies. Participants will receive gecacitinib hydr...